Jefferson Health’s Sidney Kimmel Cancer Center named vice president for cancer disparities

ADD Topic TO E-mail NOTIFICATION

Obtain an e mail when new articles are published

Enter your e mail address to get an e mail when new articles are published on . ” information-action=subscribe> Subscribe

We could not approach your request. Attempt once again later. If you nevertheless have this difficulty, please make contact with customerservice@slackinc.com.

Back to Healio

Edith P. Mitchell, MD, MACP, FCCP, FRCP (London), has been named corporate vice president for cancer disparities at Jefferson Health’s Sidney Kimmel Cancer Center.

In this new function, Mitchell will be accountable for creating and coordinating cancer care disparities operations across Jefferson.

She will oversee a group focused on cancer care good quality and price-effectiveness, as properly as patient-centered outcomes. It will also concentrate on identifying and eliminating barriers to care, especially these associated to socioeconomic, racial or ethnic disparities and social determinants of overall health.

Edith P. Mitchell

“Dr. Mitchell has had a outstanding profession committed to eliminating overall health disparities that have an effect on also a lot of folks and communities in the Philadelphia location and beyond.” Andrew Chapman, DO, director of the Sidney Kimmel Cancer Center and executive vice president of oncology solutions at Jefferson Wellness, according to a news release. “Her operate with neighborhood overall health workers enhanced minority participation in clinical trials and brought cancer screening to neighborhoods lacking access to preventive care.” Dr. Mitchell’s knowledge and dedication to healthcare are invaluable to the Sidney Kimmel Cancer Center in our commitment to delivering higher-good quality cancer care all through the area.”

Mitchell is also director of the Center to Eradicate Cancer Disparities and clinical professor of medicine and healthcare oncology at Jefferson Health’s Sidney Kimmel Cancer Center. She joined Jefferson in 1995.

Her study has focused on barriers to participation in clinical trials, as properly as evaluating new drugs and new therapy regimens for individuals with breast cancer or gastrointestinal cancer.